Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
Public ClinicalTrials.gov record NCT03102047. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study to Assess the Activity of PD-L1 Inhibition With Durvalumab (MEDI4736) After Chemo-Radiotherapy in Patients With Stage II-IV Microsatellite Stable (MSS) Rectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being done to look at the safety and response to the investigational drug durvalumab (MEDI4736) following chemo-radiation therapy for patients with MSS stage II to IV rectal cancer. Durvalumab recognizes specific proteins on the surface of cancer cells and triggers the immune system to destroy the cancer cells. The chemoRT portion of the treatment will be completed just before the course of durvalumab is initiated. In order to learn more about certain characteristics of rectal cancer tumors, this study includes special research tests using samples from diagnostic tumors, a tissue sample from tumors removed during surgery, fresh tumor samples from an area where the cancer has recurred, and blood samples.
Study identification
- NCT ID
- NCT03102047
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 14, 2018 (Actual)
- Primary completion
- Feb 22, 2021 (Actual)
- Completion
- Dec 30, 2021 (Actual)
- Last update posted
- Apr 20, 2022
2018 – 2021
United States locations
- U.S. sites
- 43
- U.S. states
- 8
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Smilow Cancer Hospital Care Center at Guilford | Guilford | Connecticut | 06437 | — |
| Smilow Cancer Hospital Care Center at Yale | New Haven | Connecticut | 06510 | — |
| Yale University, Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Smilow Cancer Hospital Care Center at North Haven | North Haven | Connecticut | 06473 | — |
| Smilow Cancer Hospital Care Center at Trumbull | Trumbull | Connecticut | 06477 | — |
| Smilow Cancer Hospital at Lawrence + Memorial Cancer Center | Waterford | Connecticut | 06385 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| Cancer Care Specialists of Central Illinois | Decatur | Illinois | 62526 | — |
| Cancer Care Specialists of Central Illinois-Crossroads Cancer Center | Effingham | Illinois | 62401 | — |
| Cancer Care Specialists of Central Illinois-Swansea | Swansea | Illinois | 62226 | — |
| University of Michigan Oncology | Ann Arbor | Michigan | 48109 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157 | — |
| Wake Forest Medical Center | Winston-Salem | North Carolina | 27157 | — |
| Strecker Cancer Center | Belpre | Ohio | 45714 | — |
| Adena Regional Medical Center | Chillicothe | Ohio | 45601 | — |
| Columbus NCORP | Columbus | Ohio | 43215 | — |
| Grant Medical Center | Columbus | Ohio | 43215 | — |
| Doctors Hospital | Columbus | Ohio | 43228 | — |
| Columbus Oncology and Hematology Associates, Inc. | Delaware | Ohio | 43015 | — |
| Delaware Health Center Grady Cancer Center | Delaware | Ohio | 43015 | — |
| Marietta Memorial Hospital | Marietta | Ohio | 45750 | — |
| Marion General Hospital | Marion | Ohio | 43302 | — |
| The Mark H. Sangmeister Center | Marion | Ohio | 43302 | — |
| Knox Community Hospital | Mount Vernon | Ohio | 43050 | — |
| Licking Memorial Hospital | Newark | Ohio | 43055 | — |
| Southern Ohio Medical Center | Port Clinton | Ohio | 45662 | — |
| Genesis Health Care Center | Zanesville | Ohio | 43701 | — |
| UPMC Hillman Cancer at Upper St Clair | Bethel Park | Pennsylvania | 15102 | — |
| UPMC Hillman Cancer Center at Mt. View | Greensburg | Pennsylvania | 15601 | — |
| AHN Cancer Institute at Jefferson | Jefferson Hills | Pennsylvania | 15025 | — |
| Forbes Regional Hospital | Monroeville | Pennsylvania | 15146 | — |
| UPMC Hillman Cancer Center at Monroeville | Monroeville | Pennsylvania | 15146 | — |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | — |
| WPAON/Medical Center Clinic | Pittsburgh | Pennsylvania | 15212 | — |
| Western Pennsylvania Hospital dba West Penn Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| UPCI Hillman/Shadyside | Pittsburgh | Pennsylvania | 15232 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| UPMC Cancer Center at Passavant OHA | Pittsburgh | Pennsylvania | 15237 | — |
| UPMC Hillman Cancer Center at Passvant HOA | Pittsburgh | Pennsylvania | 15237 | — |
| UPMC Hillman Cancer Center at Washington | Washington | Pennsylvania | 15301 | — |
| West Virginia University Medicine | Morgantown | West Virginia | 26506 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03102047, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2022 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03102047 live on ClinicalTrials.gov.